General Introduction 

In our department, there are 2 chief surgeons, 5 associated chief doctors, 7 attending surgeons and 4 residents. Our department has 89 beds for thyroid patients. Each year, over 25000 outpatients and over 3000 operations are performed here.

 

The Department of Thyroid Neck Tumor is a specialized department established on the basis of the professional treatment group for head and neck cancer established earlier in China. It is now the secretariat of the China Anti-Cancer Association Thyroid Cancer Committee and the secretariat of the Secretariat, and the head of the China Cancer Society. The secretariat of the secretariat of the committee, the chairman of the Tianjin Thyroid Cancer Committee. The founder of the discipline is Professor Li Shuling, the academic leader of the famous head and neck cancer in China. At the beginning of 2005, the head and neck department was divided into two separate departments to meet the needs of the expansion and development of the department. Prof. Gao Ming, the academic leader, is the vice president and doctoral tutor. He is the chairman of the China Cancer Society's Thyroid Cancer Professional Committee, the chairman of the China Cancer Society's head and neck cancer professional committee, and the chairman of the Tianjin Thyroid Cancer Committee.

 

The department not only inherits the exquisite surgical skills and rigorous work attitude of the older generation of medical workers, but also follows the medical characteristics of the original head and neck department, such as thyroid surgery and carotid surgery, especially in head and neck cancer. The treatment is more representative and characteristic.

 

Tianjin Medical University Cancer Hospital Thyroid Neck Tumor Department has strong clinical and technical skills, skilled surgical expertise, and experienced and high-quality head and neck oncologists, with world-class treatment methods and means. 

 

Faculty / Staff


Prof. Xiangqian Zheng, M.D., deputy director

Standing Council Member of Youth Council of CACA; the Secretary General of Chinese Association of Thyroid Oncology, CATO; the Secretary General of Head of Neck Oncology of CACA


Prof. Ming Gao, M.D.

President, Head and Neck Oncology of CACA ; Former President, Chinese Association of Thyroid Oncology, CATO; Vice president, Chinese society of medical oncology; Associate Editor-in-Chief, ThyroidChinese version; Tianjin 131 Innovative Talents Project—First Class 

 

Dr. Yigong Li, M.D., 

Expert in endoscopic thyroidectomy and video assisted lateral neck dissection

 

Prof. Yang Yu, M.D.

Vice president of Youth Council of CATO; Committee member of CATO 

 

Dr. Wenyuan Cheng, M.D.

Expert in early stage and advance stage thyroid cancer surgery

 

Dr. Yan Zhang, M.D.

Expert in early stage and advance stage thyroid cancer surgery

 

Dr. Xiaoyong Yang, M.D.

Expert in early stage and advance stage thyroid cancer surgery 


Dr. Songfeng Wei

Expert in early stage and advance stage thyroid cancer surgery

 

Dr. Junyi Wang

Expert in early stage and advance stage thyroid cancer surgery


 

Research

Seven National Science Foundation of China:

1. The functional analysis of C14X in the development of thyroid gland and tumorigenesis of thyroid cancer.

2. Candidate gene for familial non-medullary thyroid cancer and its verification.

3. The mechanism of CDK7 mediated transcription addiction in undifferentiated thyroid cancer.

4. Tumor derived ScR+ microparticle in DC immune tolerance: new strategy for immune evasion in thyroid cancer.

5. Aurora-A inhibits LKB1/AMPK pathway to promote the aggressiveness and metastasis in malignant tumors.

6. Biological function and molecular mechanism of novel MDM2 phosphorylation site S232 and ARF mediated S232.

7. TGF-b regulates chemo-resistancy via miR-21 and miR-181 and its underlying mechanism.    

 

Clinical Service

We have carried out standardized surgical techniques which include lobectomy and central compartment neck dissection, total thyroidectomy and neck dissection. In addition, we carried out Endoscopic thyroidectomy and video assisted lateral neck dissection (Micolli).

 

Clinical trials

There were several registered clinical trials that was led by our department:

2009: Efficacy and toxicity of sorafenib in the treatment of radioactive iodine-refractory differentiated thyroid cancer.

2013: Efficacy and toxicity of Vandetanib in the treatment of radioactive iodine-refractory differentiated thyroid cancer.

2015: Efficacy and toxicity of  Anlotinib in the treatment of advanced medullary thyroid cancer.

2015: Efficacy and toxicity of  Anlotinib in the treatment of radioactive iodine-refractory differentiated thyroid cancer.

2019: : Efficacy and toxicity of  BLU-667 in the treatment of advanced medullary thyroid cancer.

Our Team
Ming Gao M.D.
Vice President
Xiangqian Zheng M.D.
Vice Director
Yigong Li M.D.